Teprotumumab Treatment Outcomes for Thyroid Eye Disease: 17 Patient Case Series

A retrospective case series of 17 patients with thyroid eye disease-related diplopia treated with teprotumumab at a single institution. The data includes Gorman diplopia scores and strabismus measurements recorded before and after treatment. The dataset was authored by Madhura A. Tamhankar and last updated on 2026-05-18.

Use Cases

• Comparing changes in subjective Gorman diplopia scores and objective ocular alignment measurements after teprotumumab treatment.
• Analyzing the variability between patient-reported and clinically measured outcomes for thyroid eye disease.
• Evaluating the efficacy of teprotumumab in improving diplopia and strabismus in a clinical cohort.

Strengths

• Includes pre- and post-treatment measurements for 17 patients meeting specific inclusion criteria.
• Reports primary and secondary endpoints: 71% of patients showed improved ocular alignment and 59% showed improved Gorman score.
• Quantifies the discordance between subjective and objective measures, observed in 41% of cases.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• Data is from a single institution with a small cohort of 17 patients, limiting generalizability.

Provenance

Source

figshare

Collection Method

Retrospective case series from a single institution.

Freshness

Last updated 2026-05-18 14:40:03; freshness should be verified.